ArticleInternational journal of cancer2026
The impact of time-to-recurrence on post-recurrence mortality in stage I-III colorectal cancer: A nationwide Danish cohort study.
Article in International journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Recurrence is a major risk factor of death following treatment for colorectal cancer (CRC). Postoperative surveillance aims to diagnose recurrence early to improve chances of cure. However, early recurrences may represent aggressive tumors associated with poor prognosis. This study investigated the association between time-to-recurrence and post-recurrence mortality in a nationwide cohort of 34,166 patients undergoing curative surgery for UICC stages I-III CRC in Denmark during 2004-2019 among which we identified 7027 recurrence patients by applying a validated recurrence detection algorithm to nationwide health registry data. Patients were followed from recurrence and until death or January 1st 2023. The time from surgery to recurrence was fitted with a restricted spline in a Cox proportional hazards model adjusted for sex, age, comorbidities, and location and pathological TNM stage of the primary CRC tumor. A total of 4025 recurrence patients died within 5 years after recurrence with 80% registered as a CRC-related cause of death. Median post-recurrence survival was 38.2 months (95% CI: 36.1-40.1 months). Relative to recurrences diagnosed at postoperative year 3 (reference), the 5-year post-recurrence CRC-specific HR was 1.36 (95% CI: 1.28-1.44) for recurrences diagnosed at 1 year, decreasing to HR = 0.67 (95% CI: 0.56-0.82) for recurrences diagnosed at year 5. In stratified analyses most recurrence sites followed this pattern, though not local and liver-only recurrences. This study suggests that time from surgery to recurrence diagnosis is prognostic of post-recurrence mortality after curative surgery for non-metastatic CRC. Early identification of recurrent tumors in the first postoperative years is of immense importance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.